07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

DiaPep277: Phase III data

Horizon Pharma plc (NASDAQ:HZNP, Dublin, Ireland) said that Clal Biotechnology Industries Ltd. (Tel Aviv:CBI, Tel Aviv, Israel) provided the Tel Aviv Stock Exchange notice of data from the double-blind, international Phase III DIA-AID 2...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Company News

Hyperion Therapeutics Inc, Clal, Weizmann Institute of Science deal

Hyperion and Clal settled an ongoing dispute related to the development of DiaPep277 and partnered to complete the Phase III DIA-AID 2 trial of the compound to treat Type I diabetes. Hyperion is responsible...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

DiaPep277: Development discontinued

Hyperion is discontinuing DiaPep277 after discovering research misconduct in development of the Type I diabetes product by employees of Hyperion's Andromeda Biotech Ltd. subsidiary. Hyperion said it uncovered evidence that some Andromeda employees colluded...
07:00 , Sep 15, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Actavis plc (NYSE:ACT) gained $3.09 to $234.38 last week after FDA's Cardiovascular and Renal Drugs Advisory Committee voted 6-4 against approval of an NDA for a fixed-dose combination of nebivolol and valsartan to treat hypertension....
02:52 , Sep 10, 2014 |  BC Extra  |  Company News

Clal, Evotec fall on DiaPep277 revelations

Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) plummeted NIS366.80 (46%) to NIS440 on Tuesday, a day after Hyperion Therapeutics Inc. (NASDAQ:HPTX) said it is terminating diabetes candidate DiaPep277 following alleged research misconduct. Hyperion gained the product...
02:14 , Sep 9, 2014 |  BC Extra  |  Company News

Scandal craters Hyperion's DiaPep277

Hyperion Therapeutics Inc. (NASDAQ:HPTX) said it is terminating diabetes candidate DiaPep277 following research misconduct -- a move that comes just three months after Hyperion spent about $20.4 million to acquire Andromeda Biotech Ltd. and the...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Company News

Clal, Hyperion deal

Hyperion will acquire Clal's Andromeda Biotech Ltd. subsidiary in a cash and stock deal. Clal will receive $12.5 million in cash and 312,869 Hyperion shares up front. The shares are valued at $8 million...
07:00 , Apr 28, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) gained $2.23 to $35.62 last week after partner AbbVie Inc. (NYSE:ABBV) submitted an NDA to FDA for its all-oral regimen comprising ABT-450 plus AbbVie's Norvir ritonavir, ABT-267 and ABT-333 with...
00:28 , Apr 25, 2014 |  BC Extra  |  Company News

Hyperion to acquire Clal's diabetes unit

Hyperion Therapeutics Inc. (NASDAQ:HPTX) will acquire the Andromeda Biotech Ltd. diabetes subsidiary of Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) in a cash and stock deal. Clal will receive an upfront payment of $12.5 million in...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Clal, Teva deal

Clal's Andromeda Biotech Ltd. subsidiary will pay Teva about $72 million to reacquire exclusive, worldwide rights to commercialize DiaPep277. The payment also covers Andromeda's repurchase of Teva's 16% equity stake in Andromeda, which granted...